Global Flow Cytometry in Oncology and Immunology Market

Report ID : 1491 | Published : 2022-12-05 | Pages: | Format: PDF/EXCEL

The market size of the Global Flow Cytometry in Oncology and Immunology Market in the year 2021 is valued at 1.69 billion and is predicted to reach 3.95 billion by the year 2030 at an 10.11% CAGR during the forecast period.

The global increase in HIV diagnoses is a significant market factor for flow cytometry, and this is because the flow cytometry technique is specifically used for HIV diagnosis. In flow cytometry, light scattering is utilized to identify cells. These cells receive particular markers known as CDs depending on the type of scattering (clusters of differentiation). The main market players are concentrating on creating new products, which is anticipated to propel market growth over the forecast year. The key elements affecting flow cytometry in the oncology and immunology market include high resolution, enhanced efficacy, and the creation of powerful statistical platforms. In addition, factors like the rising acceptance of new technology and the rising use of flow cytometry in medical research are anticipated to boost market expansion throughout the estimated period. Furthermore, the market is expected to grow in the coming years due to the increasing prevalence of cancer and HIV/AIDS patients worldwide. On the other hand, the demand for flow cytometry in oncology and immunology is predicted to be hindered by a lack of technicians, awareness of the applications of flow cytometry, and the high costs of flow cytometry equipment and reagent.

Market Segmentation:

The flow cytometry in the oncology and immunology market is segmented on the offering technology, type, applications and end users. Based on offerings, the market is segmented into products (Instruments, Reagents and Consumables, and Software) and services. Based on technology, flow cytometry in the oncology and immunology market is segmented into cell-based flow cytometry and bead-based flow cytometry. Based on the type, the flow cytometry in the oncology and immunology market is segmented into immunology and oncology. Based on applications, flow cytometry in the oncology and immunology market is segmented into translational and clinical research. Based on end-users, flow cytometry in the oncology and immunology market is segmented into hospitals, diagnostic laboratories, reference laboratories, pharmaceutical and biotechnology companies, academic research institutes, contract research organizations and others.

Based on technology, the cell-based theory segment is a major contributor to the flow cytometry in the oncology and immunology market.

The market's leading segment is cell-based theory. Rising interest in early diagnosis and a growing understanding of the benefits of cell-based diagnostics account for the largest share of this growth. The development of new tools, labels, affinity reagents, software, and algorithms, as well as advancements in cell-based assay technologies, are also anticipated to increase usage in the future years. Bead tests are used in studies on infectious diseases. The market for these assays is anticipated to grow profitably throughout the projection period due to advancements in molecular engineering and monoclonal antibody manufacturing and their advantages, such as cost-effectiveness, low sample requirement, and quick turnaround times.

The pharmaceutical and biotechnology companies segment witnessed growth at a rapid rate.

Pharmaceutical and biotechnology companies grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the expected time. This high percentage can be attributed to increased R&D activities for cancer and infectious diseases like COVID-19. Additionally, it is projected that increased R&D investments in the biotechnology and pharmaceutical industries will promote market expansion. The clinical diagnostic market is anticipated to grow at the fastest rate due to the growing demand for cheap illness diagnosis and the advantages of flow cytometry in disease detection, such as quicker and more accurate results.

The North American flow cytometry in the oncology and immunology market holds a significant regional revenue share.

The North American flow cytometry in the oncology and immunology market is expected to register the highest market share in revenue shortly, Government funding and support for R&D initiatives, increased awareness of healthcare diagnostics, and an increase in the number of cancer patients in the region are all factors contributing to the market growth in this area. Additionally, this region's market is expanding due to rising pharmaceutical industry R&D activities. In addition, Asia Pacific is projected to grow rapidly in the global flow cytometry in the oncology and immunology market due to the rising prevalence of autoimmune diseases, growing healthcare awareness, rising healthcare investments and collaborations, and regional market players expanding.

Competitive Landscape

Some major key players in the flow cytometry in oncology and immunology market are "agilent technologies, inc, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Cytek Biosciences, Inc.,, Danaher Corporation, DiaSorin S.p.A (Luminex Corporation),Enzi Biochem Inc., Laboratory Corporation of America Holdings, Merck KGaA, Miltenyi Biotec, NeoGenomics Laboratories, Inc., OPKO Health, Inc., Sony Group Corporation and Thermo Fisher Scientific Inc.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Flow Cytometry in Oncology and Immunology Market Snapshot

Chapter 4. Global Flow Cytometry in Oncology and Immunology Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Offering Estimates & Trend Analysis

5.1. by Offering & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Offering:

5.2.1. Products

5.2.1.1. Instruments

5.2.1.2. Reagents and Consumables

5.2.1.3. Software

5.2.2. Services

Chapter 6. Market Segmentation 2: by Technology Estimates & Trend Analysis

6.1. by Technology & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Technology:

6.2.1. Cell-Based Flow Cytometry

6.2.2. Bead-Based Flow Cytometry

Chapter 7. Market Segmentation 3: by Type Estimates & Trend Analysis

7.1. by Type & Market Share, 2019 & 2030

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Type:

7.2.1. Immunology

7.2.2. Oncology

7.2.2.1. Hematological Malignancies

7.2.2.1.1. Hematological Malignancies (by Type)

7.2.2.1.1.1. Lymphoma

7.2.2.1.1.2. Leukemia

7.2.2.1.1.3. Myeloma

7.2.2.1.1.4. Other Hematological Malignancies

7.2.2.1.2. Hematological Malignancies (by Technology)

7.2.2.2.  Solid Tumor

7.2.2.3. Solid Tumor (by Type)

7.2.2.3.1. Breast Cancer

7.2.2.3.2. Prostate Cancer

7.2.2.3.3. Colorectal Cancer

7.2.2.3.4. Lung Cancer

7.2.2.3.5. Liver Cancer

7.2.2.3.6. Ovarian Cancer

7.2.2.3.7. Other Solid Tumors

7.2.2.4. Solid Tumor (by Technology)

Chapter 8. Market Segmentation 4: by Application Estimates & Trend Analysis

8.1. by Application & Market Share, 2019 & 2030

8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Application:

8.2.1. Translational Research

8.2.2. Clinical Research

8.2.2.1. Screening and Diagnostics

8.2.2.2. Monitoring and Treatment

Chapter 9. Market Segmentation 5: by End User Estimates & Trend Analysis

9.1. by End User & Market Share, 2019 & 2030

9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by End User:

9.2.1. Hospitals, Diagnostic Laboratories, and Reference Laboratories

9.2.2. Pharmaceutical and Biotechnology Companies

9.2.3. Academic Research Institutes

9.2.4. Contract Research Organizations

9.2.5. Others

Chapter 10. Flow Cytometry in Oncology and Immunology Market Segmentation 8: Regional Estimates & Trend Analysis

10.1. North America

10.1.1. North America Flow Cytometry in Oncology and Immunology Market Revenue (US$ Million) Estimates and Forecasts by Offering, 2022-2030

10.1.2. North America Flow Cytometry in Oncology and Immunology Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2022-2030

10.1.3. North America Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Type, 2022-2030

10.1.4. North America Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Application, 2022-2030

10.1.5. North America Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by End User, 2022-2030

10.1.6. North America Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Model, 2022-2030

10.1.7. xx Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Delivery Mode, 2022-2030

10.1.8. North America Flow Cytometry in Oncology and Immunology Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

10.2. Europe

10.2.1. Europe Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Offering, 2022-2030

10.2.2. Europe Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Technology, 2022-2030

10.2.3. Europe Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Type, 2022-2030

10.2.4. Europe Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Application, 2022-2030

10.2.5. Europe Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by End User, 2022-2030

10.2.6. Europe Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Model, 2022-2030

10.2.7. Europe Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Delivery Mode, 2022-2030

10.2.8. Europe Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by country, 2022-2030

10.3. Asia Pacific

10.3.1. Asia Pacific Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Offering, 2022-2030

10.3.2. Asia Pacific Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Technology, 2022-2030

10.3.3. Asia-Pacific Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Type, 2022-2030

10.3.4. Asia Pacific Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Application, 2022-2030

10.3.5. Asia Pacific Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by End User, 2022-2030

10.3.6. Asia Pacific Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Model, 2022-2030

10.3.7. Asia Pacific Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Delivery Mode, 2022-2030

10.3.8. Asia Pacific Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by country, 2022-2030

10.4. Latin America

10.4.1. Latin America Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Offering, 2022-2030

10.4.2. Latin America Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Technology, 2022-2030

10.4.3. Latin America Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Type, 2022-2030

10.4.4. Latin America Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Application, 2022-2030

10.4.5. Latin America Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by End User, 2022-2030

10.4.6. Latin America Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Model, 2022-2030

10.4.7. Latin America Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Delivery Mode, 2022-2030

10.4.8. Latin America Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by country, 2022-2030

10.5. Middle East & Africa

10.5.1. Middle East & Africa Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Offering, 2022-2030

10.5.2. Middle East & Africa Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Technology, 2022-2030

10.5.3. Middle East & Africa Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Type, 2022-2030

10.5.4. Middle East & Africa Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Application, 2022-2030

10.5.5. Middle East & Africa Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by End User, 2022-2030

10.5.6. Middle East & Africa Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Model, 2022-2030

10.5.7. Middle East & Africa Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by Delivery Mode, 2022-2030

10.5.8. Middle East & Africa Flow Cytometry in Oncology and Immunology Market revenue (US$ Million) by country, 2022-2030

Chapter 11. Competitive Landscape

11.1. Major Mergers and Acquisitions/Strategic Alliances

11.2. Company Profiles

11.2.1. Agilent Technologies, Inc.

11.2.2. Becton, Dickinson, and Company

11.2.3. Bio-Rad Laboratories, Inc.

11.2.4. Cell Signaling Technology, Inc.

11.2.5. Cytec Biosciences, Inc.

11.2.6. Danaher Corporation

11.2.7. Diasporic S.p.A (Luminex Corporation)

11.2.8. Enzi Beachem Inc.

11.2.9. Laboratory Corporation of America Holdings

11.2.10. Merck Kagan

11.2.11. Millenia Biotic

11.2.12. Neo Genomics Laboratories, Inc.

11.2.13. OPKO Health, Inc.

11.2.14. Sony Group Corporation

11.2.15. Thermos Fisher Scientific Inc.

11.2.16. Other Prominent Players

By Offering

  • Products
  • Instruments
  • Reagents and Consumables
  • Software
  • Services

 

By Technology

  • Cell-Based Flow Cytometry
  • Bead-Based Flow Cytometry

 

By Type

  • Immunology
  • Oncology
    • Hematological Malignancies
      • Hematological Malignancies (by Type)
        • Lymphoma
        • Leukemia
        • Myeloma
        • Other Hematological Malignancies
      • Hematological Malignancies (by Technology)
    • Solid Tumor
      • Solid Tumor (by Type)
        • Breast Cancer
        • Prostate Cancer
        • Colorectal Cancer
        • Lung Cancer
        • Liver Cancer
        • Ovarian Cancer
        • Other Solid Tumors
      • Solid Tumor (by Technology)

 

By Application

  • Translational Research
  • Clinical Research
    • Screening and Diagnostics
    • Monitoring and Treatment

 

By End User

  • Hospitals, Diagnostic Laboratories, and Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic Research Institutes
  • Contract Research Organizations
  • Others

 

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients